Now Reading: Gland Pharma Q1 net jumps 47% to Rs 317 crore on revenue
-
01
Gland Pharma Q1 net jumps 47% to Rs 317 crore on revenue
Gland Pharma reported a 47% year-on-year jump in consolidated net profit to Rs 317 crore for the June quarter, driven by a 20% rise in revenue to Rs 1,800.3 crore. Sequentially, net…
The Story in Brief
Gland Pharma reported a 47% year-on-year jump in consolidated net profit to Rs 317 crore for the June quarter, driven by a 20% rise in revenue to Rs 1,800.3 crore. Sequentially, net profit fell 14% while revenue inched up 3%. The company credited growth to new product launches from its CDMO portfolio and strong customer demand.
The drugmaker also announced a strategic manufacturing and supply deal with a global pharma company covering a portfolio of sterile injectable products. The agreement spans 55 SKUs across three sites, with potential annualised revenue of $90-100 million once fully commercialised. Technology transfer is expected within two years, and revenue from the pact may begin only from calendar 2029.
The Indian Opinion
The narrative of unbroken success for Indian pharma often ignores the lumpy nature of contract manufacturing. Gland's 47% profit jump is real, but the 14% sequential decline and the staggering five-year wait for CDMO revenue from the new pact show the gap between an announcement and actual earnings. The real test will come in calendar 2029 when those 55 SKUs start generating the promised $90-100 million annually. Until then, shareholders are betting on execution, not just hype.
Source: thehindu.com
This story was synthesised by AI from the source linked above.
